Angiotech, Haemacure combine for three deals and financing
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals and Haemacure have sealed a trio of deals that would see the latter license its Hemaseel fibrin and thrombin technologies in return for enough financing to fund its operations for the next 10-12 months.